soul trial oral semaglutide cardiovascular outcomes 2024 nejm Cuts Risk by 14% in PDF) Oral Semaglutide and Cardiovascular

Those are the drugs the Wegovy label singles out for increased monitoring

In the SURMOUNT-1 trial, patients on tirzepatide 15 mg weekly lost an average of 20.9% body weight over 72 weeks, outperforming semaglutide in head-to-head comparisons

Sometimes, eye exercises may be recommended to help improve vision or slow the decline in visual acuity that often occurs with aging

GLP-1 medications are getting a lot of press lately, but they are almost exclusively injectables

This established profile gives prescribers, patients, and insurers high confidence in its risk-benefit ratio, something retatrutide cannot yet match in 2026

It is soluble in water, dilute alcohols, liquid ammonia, and dimethylformamide, but insoluble in alcohols, ethers, and acetone